|
Futura Medical PLC announced on Tuesday that its erectile dysfunction treatment gel Eroxon is now available for purchase in the UK. Shares in Futura were up 8.0% to 46.85 pence each in London on Tuesday afternoon. Futura, headquartered in Guildford, Surrey, is a pharmaceutical company currently focused on sexual health products. These are based on its proprietary, transdermal DermaSys drug delivery technology. Eroxon, or MED3000, is Futura’s topical gel formulation for the treatment of erectile dysfunction. It is online through retailer Boots and in store. The company’s EU and UK distribution partner is Cooper Consumer Health, an independent self-care organisation headquartered in Paris. Futura claims that MED3000 is ‘fast-acting with minimal side effects’. It is the first pan-European topical ED treatment product available for purchase over the counter and without requiring a prescription. Chief Executive Officer James Barder said: ‘We are pleased to confirm that Eroxon is available in the UK from today. This is a significant milestone for the company as our distribution partners continue to increase the availability of Eroxon across different markets. ‘ED is a growing problem, and we believe that today’s announcement will be welcomed by many men suffering from ED for whom current front-line treatments for ED are unsuitable.’ Futura added: ‘The prevalence of ED disrupts the lives of at least 1 in 5 men globally with around 22 million men suffering ED in the US and 20 million men in the UK, France, Italy, Spain and Germany. ED is a growing problem, with around half of men over the age of 40 experiencing ED and a quarter of men diagnosed with ED now being under the age of 40.’ Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
